Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.
|Translated title of the contribution||Transarterial chemoembolization for treatment of hepatocellular carcinoma|
|Number of pages||8|
|Journal||Medecine et Hygiene|
|State||Published - May 21 2003|
All Science Journal Classification (ASJC) codes